China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)

被引：10

作者：

Shi, Yuankai ^{[1
,2
]}

Sun, Yan ^{[1
,2
]}

Ding, Cuimin ^{[3
]}

Wang, Ziping ^{[1
,2
]}

Wang, Changli ^{[4
]}

Wang, Zheng ^{[5
]}

Bai, Chong ^{[6
]}

Bai, Chunxue ^{[7
]}

Feng, Jifeng ^{[8
]}

Liu, Xiaoqing ^{[9
]}

Li, Fang ^{[10
]}

Yang, Yue ^{[11
]}

Shu, Yongqian ^{[12
]}

Wu, Milu ^{[13
]}

He, Jianxing ^{[14
]}

Zhang, Yiping ^{[15
]}

Zhang, Shucai ^{[16
]}

Chen, Gongyan ^{[17
]}

Luo, Honghe ^{[18
]}

Luo, Rongcheng ^{[19
]}

Zhou, Caicun ^{[20
]}

Zhou, Yanbin ^{[18
]}

Pang, Qingsong ^{[4
]}

Zhao, Hong ^{[10
]}

Zhao, Qiong ^{[21
]}

Gu, Aiqin ^{[22
]}

Ling, Yang ^{[23
]}

Huang, Cheng ^{[24
]}

Han, Baohui ^{[22
]}

Jiao, Shunchang ^{[10
]}

Jiao, Hong ^{[22
]}

机构：

[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China

[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Beijing 100021, Peoples R China

[3] Hebei Med Univ, Hosp 4, Shijiazhuang 050000, Peoples R China

[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin 300070, Peoples R China

[5] Shenzhen Peoples Hosp, Shenzhen 518020, Peoples R China

[6] Second Mil Med Univ, Changhai Hosp, Shanghai 200433, Peoples R China

[7] Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China

[8] Jiangsu Canc Hosp, Nanjing 210009, Peoples R China

[9] 307th Hosp Chinese Peoples Liberat Army, Beijing 100071, Peoples R China

[10] Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China

[11] Beijing Canc Hosp, Beijing 100142, Peoples R China

[12] Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China

[13] Qinghai Univ, Affiliated Hosp, Xining 810000, Peoples R China

[14] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou 510000, Guangdong, Peoples R China

[15] Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China

[16] Capital Med Univ, Beijing Chest Hosp, Beijing 101149, Peoples R China

[17] Harbin Med Univ, Canc Hosp, Harbin 150081, Peoples R China

[18] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China

[19] Nanfang Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China

[20] Tongji Univ, Affiliated Shanghai Pulm Hosp, Shanghai 200433, Peoples R China

[21] Zhejiang Univ, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China

[22] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 22CHANGZHOU, Peoples R China

[23] Changzhou Fourth Peoples Hosp, Changzhou 213001, Peoples R China

[24] Fujian Canc Hosp, Fuzhou 350014, Peoples R China

来源：

JOURNAL OF THORACIC DISEASE | 2015年 / 7卷 / 10期

关键词：

OPEN-LABEL; PHASE-III; 1ST-LINE TREATMENT; GEFITINIB; MULTICENTER; CHEMOTHERAPY; ERLOTINIB; PLACEBO; ADENOCARCINOMA; MUTATIONS;

D O I：

10.3978/j.issn.2072-1439.2015.10.25

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：E468 / E472

页数：5

共 28 条

[1] 梁智勇, 2011, [中华病理学杂志, Chinese Journal of Pathology], V40, P700
[2] [Anonymous], 15 WORLD C LUNG CANC
[3] [Anonymous], INTERPRETATION CLIN
[4] [Anonymous], MIMS ONCOLOGY GUIDE
[5] Bosworth A, 2013, J CLIN ONCOL, V31
[6] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Cappuzzo, Federico
Ciuleanu, Tudor
Stelmakh, Lilia
Cicenas, Saulius
Szczesna, Aleksandra
Juhasz, Erzsebet
Esteban, Emilio
Molinier, Olivier
Brugger, Wolfram
Melezinek, Ivan
Klingelschmitt, Gaelle
Klughammer, Barbara
Giaccone, Giuseppe
[J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
[7] Annual report on status of cancer in China, 2011
Chen, Wanqing
Zheng, Rongshou
Zeng, Hongmei
Zhang, Siwei
He, Jie
[J]. CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (01) : 2 - 12
[8] Chinese Association of Oncologists, 2014, Zhonghua Zhong Liu Za Zhi, V36, P555
[9] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Ciuleanu, Tudor
Stelmakh, Lilia
Cicenas, Saulius
Miliauskas, Skaidrius
Grigorescu, Alexandru Calin
Hillenbach, Carina
Johannsdottir, Hrefna Kristin
Klughammer, Barbara
Esteban Gonzalez, Emilio
[J]. LANCET ONCOLOGY, 2012, 13 (03) : 300 - 308
[10] A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
Hu, Xingsheng
Han, Baohui
Gu, Aiqin
Zhang, Yiping
Jiao, Shun Chang
Wang, Chang-li
He, Jintao
Jia, Xueke
Zhang, Li
Peng, Jiewen
Wu, Meina
Ying, Kejing
Wang, Junye
Ma, Kewei
Zhang, Shucai
You, Changxuan
Tan, Fenlai
Wang, Yinxiang
Ding, Lieming
Sun, Yan
[J]. LUNG CANCER, 2014, 86 (02) : 207 - 212

← 1 2 3 →